Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Natalie I Vokes, David R. Gandara, Ahmet Sezer, Saadettin Kilickap, Mahmut Gumus, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, Dmitry Bentsion, Jinrui Liu, Nicholas Giangreco, Fang Wang, Siyu Li, Israel Lowy, Jean-Francois Pouliot, Giuseppe Gullo, Petra Rietschel, Vladimir Jankovic
Institutions: The University of Texas MD Anderson Cancer Center, University of California Davis Medical Center, UC Davis Comprehensive Cancer Center, Başkent University, Istinye University, Istanbul Medeniyet University, Dnipro State Medical University, Istanbul University-Cerrahpaşa, Bezmiâlem Vakıf Üniversitesi, Trakya University, Regeneron (United States)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4379281507